ResMed

RMD

Market cap $37.3B

ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maintaining solid cash flow and margin, has a low-debt capital structure, and is fairly valued.

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RL, EAT, FTI and RMD hold promise.

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed's U.S. presence and strengthen the company's distribution capacity to better serve patients and providers across North America.

Invesco International Growth Fund underperformed most in industrials, consumer discretionary and communication services, all due to stock selection. We initiated five positions during the quarter, four of which we can discuss now. We eliminated seven positions. Relative to its index, the fund outperformed most in financials, health care and energy, all due to stock selection.

The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. APH, GE, RMD and AMP are some such stocks.

Resmed shares rise after Q2 EPS and revenues beat expectations, with the gross and operating margins expanding sharply across core segments.

The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1 boom a lift, not a threat, to sales.

The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell